Pharma manufacturer Strides Shasun said it received approval from the United States Food and Drug Administration to sell a generic version of Merck’s Periactin tablets.
The US market for Cyproheptadine Hydrochloride Tablets is approximately USD 20 Million, according to IQVIA, the company said.
The drug is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, sneezing, hives, and itching.
It will be manufactured at the company’s Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market.
Shasun Strides is a vertically integrated pharmaceutical company headquartered in Bangalore.
It operates in both regulated markets and emerging markets.
The company has 74 cumulative generic drug approval filings with USFDA of which 46 ANDAs have been approved as of date.
The remaining 28 are pending approval, it said.